doi: 10.1186/1743-7075-7-79 233 ShuklaSKCookDMeyerJVernonSDLeTClevidenceDet al
There is a strong and growing body of evidence that suggests that Thymosin Beta is highly effective at treating and preventing the relapse of various autoimmune diseases
What if I experience nausea or other side effects? Mild nausea, fatigue, or constipation can happen early on
People discontinue medication for many reasons such as cost, insurance denials, shortages, plateaus, or side effects
Additionally, they offer no proven benefit beyond tirzepatide's substantial weight loss effects and may worsen anxiety or sleep disturbances
Food and Drug Administration: (May 2022) Approved as adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus (November 2023) Approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (December 2024) Expanded indication for moderate-to-severe obstructive sleep apnea in adults with obesity Classified as first-in-class dual GIP/GLP-1 receptor agonist Not approved for type 1 diabetes mellitus or as monotherapy in patients with history of pancreatitis International Regulatory Approvals GLP2 has received regulatory approval in multiple jurisdictions: European Union (September 2022) Type 2 diabetes treatment United Kingdom (November 2023) Expanded to include weight management Canada (November 2022) Type 2 diabetes indication Australia (December 2022) Type 2 diabetes treatment Additional regulatory reviews ongoing in other countries Warnings and Contraindications Important safety considerations include: Boxed Warning for thyroid C-cell tumor risk (based on rodent studies
